Lite Strategy (LITS) Stock Overview
A clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LITS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeLite Strategy, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.22 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$0.95 |
| Beta | 0.083 |
| 1 Month Change | 5.17% |
| 3 Month Change | 18.45% |
| 1 Year Change | -41.63% |
| 3 Year Change | -82.84% |
| 5 Year Change | -97.73% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| LITS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.0% | 1.3% | 2.2% |
| 1Y | -41.6% | 42.0% | 31.1% |
Return vs Industry: LITS underperformed the US Biotechs industry which returned 42% over the past year.
Return vs Market: LITS underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| LITS volatility | |
|---|---|
| LITS Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LITS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LITS's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4 | Jay File | www.litestrategy.com |
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Lite Strategy, Inc. Fundamentals Summary
| LITS fundamental statistics | |
|---|---|
| Market cap | US$44.36m |
| Earnings (TTM) | -US$39.70m |
| Revenue (TTM) | n/a |
Is LITS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LITS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$2.11m |
| Gross Profit | -US$2.11m |
| Other Expenses | US$37.59m |
| Earnings | -US$39.70m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LITS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 17:57 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lite Strategy, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen V. Byrne | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |
| Daniel Brims | Cantor Fitzgerald & Co. |